Efficacy of three-dimensional conformal radiotherapy in treatment of prostate cancer:a meta-analysis
Zhang Lijin,Wu Bin,Yu Bo,Sha Sha,Wang Caiping,Yuan Jun,Zha Zhenlei,Zhao Hu
Department of Urology (Zhang LJ,Wu B,Wang CP,Yuan J,Zha ZL,Zhao H),Department of Radiation Oncology (Yu B,Sha S),Affiliated Jiangyin Hospital of the Southeast University Medical College,Jiangyin 214400,China
Abstract：Objective To systematically compare the efficacy of three-dimensional conformal radiotherapy (3D-CRT) versus intensity-modulated radiotherapy (IMRT) in the treatment of prostate cancer (PCa). Methods Clinical comparative studies of IMRT and 3D-CRT in the treatment of PCa were collected from PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), and Wanfang Data after two independent researchers developed the strategy and inclusion and exclusion criteria for the literature search. Articles published up to February 2017 were searched for, and the languages of publications were restricted to English and Chinese. Clinical meta-analysis of the data from the relevant studies was performed using the RevMan5.3 software. Results A total of 15 relevant retrospective cohort studies were collected from the databases in strict accordance to the search strategy and inclusion and excluding criteria. There were 4608 PCa patients, including 2229 in the IMRT group and 2379 in the 3D-CRT group. IMRT and 3D-CRT had similar adverse effects in terms of early-stage (odds ratio[OR]=0.77, 95% confidence interval[CI]:0.43-1.40, P=0.390) and late-stage (OR=0.75, 95%CI:0.55-1.04, P=0.080) urinary tract injury. However, IMRT led to reduced early-stage (OR=0.47, 95%CI:0.27-0.82, P=0.008) and late-stage (OR=0.52, 95%CI:0.35-0.78, P=0.001) intestinal injury compared with 3D-CRT. Meanwhile, the biochemical recurrence-free survival rate was also significantly higher in the IMRT group than in the 3D-CRT group (OR=1.87, 95%CI:1.51-2.32, P=0.000). Conclusions IMRT is more protective against intestinal injury with a higher biochemical recurrence-free survival rate compared with 3D-CRT during the treatment of PCa.
Zhang Lijin,Wu Bin,Yu Bo et al. Efficacy of three-dimensional conformal radiotherapy in treatment of prostate cancer:a meta-analysis[J]. Chinese Journal of Radiation Oncology, 2017, 26(9): 1050-1054.
[1] Tsoi KK,Hirai HW,Chan FC,et al. Cancer burden with ageing population in urban regions in China:projection on cancer registry data from World Health Organization[J].Br Med Bull,2017,121(1):83-94.DOI:10.1093/bmb/ldw050. [2] 侯赞,王雪桃,柏森.前列腺癌自适应放射治疗研究现状及进展[J].中华放射医学与防护杂志,2015,35(2):157-160.DOI:10.3760/cma.j.issn.0254-5098.2015.02.020. Hou Z,Wang XT,Bai S.Current status and progress of adaptive radiotherapy for prostate cancer[J].Chin J Radiat Med Prot,2015,35(2):157-160.DOI:10.3760/cma.j.issn.0254-5098.2015.02.020. [3] Holch P,Henry AM,Davidson S,et al. Acute and late adverse events associated with radical radiation therapy prostate cancer treatment:a systematic review of clinician and patient toxicity reporting in randomized controlled trials[J].Int J Radiat Oncol Biol Phys,2017,97(3):495-510.DOI:10.1016/j.ijrobp.2016.11.008. [4] Zeng XT,Zhang YG,Kwong JS,et al. The methodological quality assessment tools for preclinical and clinical studies,systematic review and meta-analysis,and clinical practice guideline:a systematic review[J].J Evid Based Med,2015,8(1):2-10.DOI:10.1111/jebm.12141. [5] Vora SA,Wong WW,Schild SE,et al. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer[J].Int J Radiat Oncol Biol Phys,2007,68(4):1053-1058.DOI:10.1016/j.ijrobp.2007.01.043. [6] Alongi F,Fiorino C,Cozzarini C,et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy[J].Radiother Oncol,2009,93(2):207-212.DOI:10.1016/j.radonc.2009.08.042. [7] Odrazka K,Dolezel M,Vanasek J,et al. Late toxicity after conformal and intensity-modulated radiation therapy for prostate cancer:impact of previous surgery for benign prostatic hyperplasia[J].Int J Urol,2010,17(9):784-790.DOI:10.1111/j.1442-2042.2010.02592.x. [8] Forsythe K,Blacksburg S,Stone N,et al. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer[J].Int J Radiat Oncol Biol Phys,2012,83(2):630-635.DOI:10.1016/j.ijrobp.2011.06.2013. [9] Sveistrup J,af Rosenschld PM,Deasy JO,et al. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance[J].Radiat Oncol,2014,9:44.DOI:10.1186/1748-717X-9-44. [10] Dolezel M,Odrazka K,Zouhar M,et al. Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer[J].Strahlenther Onkol,2015,191(4):338-346.DOI:10.1007/s00066-014-0806-y. [11] Someya M,Hori M,Tateoka K,et al. Results and DVH analysis of late rectal bleeding in patients treated with 3D-CRT or IMRT for localized prostate cancer[J].J Radiat Res,2015,56(1):122-127.DOI:10.1093/jrr/rru080. [12] Wortel RC,Incrocci L,Pos FJ,et al. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients[J].Int J Radiat Oncol Biol Phys,2015,91(4):737-744.DOI:10.1016/j.ijrobp.2014.12.017. [13] Shimizuguchi T,Nihei K,Okano T,et al. A comparison of clinical outcomes between three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer[J].Int J Clin Oncol,2017,22(2):373-379.DOI:10.1007/s10147-016-1057-y. [14] Wortel RC,Incrocci L,Pos FJ,et al. Late side effects after image guided intensity modulated radiation therapy compared to 3D-conformal radiation therapy for prostate cancer:results from 2 prospective cohorts[J].Int J Radiat Oncol Biol Phys,2016,95(2):680-689.DOI:10.1016/j.ijrobp.2016.01.031. [15] Kupelian PA,Reddy CA,Carlson TP,et al. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer[J].Int J Radiat Oncol Biol Phys,2002,53(4):904-912.DOI:10.1016/S0360-3016(02)02836-5. [16] Sharma NK,Li T,Horwitz EM,et al. Intensity modulated radiation therapy reduces gastrointestinal morbidity in patients treated with androgen deprivation therapy for prostate cancer[J].Int J Radiat Oncol Biol Phys,2007,69(3):S10.DOI:10.1016/j.ijrobp.2007.07.019. [17] Kim H,Kim JW,Hong SJ,et al. Treatment outcome of localized prostate cancer by 70 Gy hypofractionated intensity-modulated radiotherapy with a customized rectal balloon[J].Radiat Oncol J,2014,32(3):187-197.DOI:10.3857/roj.2014.32.3.187. [18] Ratnayake G,Martin J,Plank A,et al. Incremental changes verses a technological quantum leap:the additional value of intensity-modulated radiotherapy beyond image-guided radiotherapy for prostate irradiation[J].J Med Imaging Radiat Oncol,2014,58(4):503-510.DOI:10.1111/1754-9485.12153. [19] Goenka A,Magsanoc JM,Pei X,et al. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy[J].Eur Urol,2011,60(6):1142-1148.DOI:10.1016/j.eururo.2011.08.006. [20] 房辉,李晔雄,余子豪,等.前列腺癌三维适形和调强放疗的初步结果[J].中华放射肿瘤学杂志,2006,15(3):197-200.DOI:10.3760/j.issn:1004-4221.2006.03.010. Fang H,Li YX,Yu ZH,et al. Three-dimensional conformal radiotherapy or intensity modulated radiation therapy for prostate cancer[J].Chin J Radiat Oncol,2006,15(3):197-200.DOI:10.3760/j.issn:1004-4221.2006.03.010. [21] Teh BS,Mai WY,Grant Ⅲ WH,et al. Intensity modulated radiotherapy (IMRT) decreases treatment-related morbidity and potentially enhances tumor control[J].Cancer Invest,2002,20(4):437-451.DOI:10.1081/CNV-120002143. [22] Jacobs BL,Zhang Y,Skolarus TA,et al. Comparative effectiveness of external-beam radiation approaches for prostate cancer[J].Eur Urol,2014,65(1):162-168.DOI:10.1016/j.eururo.2012.06.055.
2017, Vol. 26 
